Haleon executives receive conditional share awards

Haleon plc (LSE/NYSE:HLN), a global leader in consumer health with a market capitalization of $46.22 billion and a "GOOD" financial health rating according to InvestingPro, disclosed the granting of conditional share awards to its top executives in a recent filing with the Securities and Exchange Commission. The awards, dated March 19, 2025, and reported on March 21, 2025, involve the issuance of ordinary shares to key personnel under the company’s Performance Share Plan, Share Value Plan, and Deferred Annual Bonus Plan.

The conditional awards are significant, with CEO Brian McNamara receiving 1,507,212 shares under the Performance Share Plan and 194,833 under the Deferred Annual Bonus Plan. Other recipients include CFO Dawn Allen and several Presidents and Chief Officers, with varying numbers of shares awarded. The awards come as Haleon’s stock trades near its 52-week high of $10.80, having delivered an impressive 25.4% return over the past year.

These awards are tied to specific performance conditions, which will be assessed at the end of a performance period concluding on December 31, 2027. Detailed performance targets are outlined in Haleon’s 2024 Annual Report and 20-F. The Share Value Plan (Buyout) awards are contingent on continued employment, while all awards are subject to malus and clawback provisions.

The transactions occurred outside a trading venue, with shares priced at nil, indicating that the executives did not pay for the shares at the time of the award.

This strategic move aligns executive compensation with company performance and shareholder interests, ensuring that Haleon’s leadership remains focused on long-term value creation. Currently trading at a P/E ratio of 24.36 and offering a dividend yield of 2.24%, Haleon appears slightly overvalued according to InvestingPro’s Fair Value analysis. The full details of these transactions can be found in the company’s 6-K filing, which reflects Haleon’s commitment to transparency in its executive remuneration practices. For deeper insights into Haleon’s valuation and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.

In other recent news, Haleon plc has completed a significant share buyback from Pfizer Inc. (NYSE:PFE), purchasing approximately 44 million shares for $170 million. This transaction marks Pfizer’s complete exit from Haleon’s shareholder base, reducing its stake from 7.3% to zero. The buyback is part of Haleon’s broader $500 million repurchase plan for 2025, and the acquired shares will be canceled, impacting the distribution of voting rights among shareholders. Additionally, Haleon has released its 2024 Annual Report and Form 20-F, providing a detailed overview of its financial performance, which is now available for public inspection. In executive news, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers acquired shares under the company’s Share Reward Plan, aligning their interests with those of shareholders. This plan is part of Haleon’s strategy to incentivize key management personnel through equity ownership. These developments are part of Haleon’s ongoing efforts to manage capital effectively and enhance shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.